Stocks Health care FHTX
NASDAQ · Health careFoghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. brought in $112.1M of revenue over the twelve months to September 30, 2026, up 357.3% from a year earlier. Net income was $9.4M, a net margin of 8.4%. In fiscal 2025 capital spending exceeded operating cash flow by $86.1M. At September 30, 2026 it held $80.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Foghorn Therapeutics Inc.
- Net worth
- Foghorn Therapeutics Inc. has a market value (market cap) of $112.8M at the latest share price, and shareholders' equity of -$14.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $30.9M (+36.8% year on year), with a net loss of $74.3M. Over the 12 months to September 30, 2026: revenue $112.1M, net income $9.4M.
- Cash flow
- In fiscal 2025 operations used $86.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Foghorn Therapeutics Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Foghorn Therapeutics Inc. does
Foghorn Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FHTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $30.9M | -$74.3M | -$1.18 | -$86.1M |
| 2024 | $22.6M | -$86.6M | -$1.58 | -$101.3M |
| 2023 | $34.2M | -$98.4M | -$2.34 | -$119.3M |
| 2022 | $19.2M | -$108.9M | -$2.62 | $192.4M |
| 2021 | $1.3M | -$101.3M | -$2.73 | -$53.6M |
| 2020 | $430K | -$68.8M | -$6.23 | -$47.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where FHTX ranks in Health care
Latest SEC filings
What Foghorn Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 925% to $83.5M versus the same quarter last year; diluted EPS $0.80 versus -$0.25.
- November 9, 2026
- October 5, 2026Passive stake changed SCHEDULE 13G/A
- October 1, 2026Restructuring or layoffs8-KFoghorn Therapeutics and Eli Lilly decided to stop development of FHD-909, prompting Foghorn to reduce its workforce by approximately 40%.
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 113% to $16.1M versus the same quarter last year; diluted EPS -$0.10 versus -$0.28.
- August 6, 2026
- June 24, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 45% to $3.3M versus the same quarter last year; diluted EPS -$0.29 versus -$0.30.
Insider trades
What the people running Foghorn Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| April 10, 2026 | Gottschalk AdrianChief Executive Officer, Director | Gave as a giftindirect | 59,208 | - |
| April 10, 2026 | Gottschalk AdrianChief Executive Officer, Director | Gave as a giftindirect | 59,208 | - |
| April 9, 2026 | Gottschalk AdrianChief Executive Officer, Director | Gave as a giftindirect | 47,497 | - |
| April 9, 2026 | Gottschalk AdrianChief Executive Officer, Director | Gave as a giftindirect | 47,497 | - |
Who owns FHTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Noubar Afeyan13D, may seek influence with 9 related filers | 27.2% | January 13, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 14.3% | October 5, 2026 |
| Fmr LLC13G, passive with 1 related filers | 11.6% | May 6, 2026 |
| Deerfield Mgmt, L.P.13G, passive with 3 related filers | 8.64% | May 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 103 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Flagship Pioneering, LLC | 12,674,120 | 0 |
| Bvf Inc | 5,842,000 | 0 |
| Fmr LLC | 5,705,958 | -341,240 |
| Deerfield Management Company, L.P. | 4,394,367 | 0 |
| BlackRock, Inc. | 2,626,832 | +261,966 |
| Raymond James Financial Inc | 2,489,978 | -112,404 |
| Euclidean Capital LLC | 1,573,761 | 0 |
| Vanguard Capital Management LLC | 1,494,611 | -478 |
| Geode Capital Management, LLC | 910,866 | +62,694 |
| Siren, L.L.C. | 720,720 | 0 |
| State Street Corp | 697,469 | +17,682 |
| Ameriprise Financial Inc | 558,685 | +109,709 |
| Renaissance Technologies LLC | 377,936 | -28,489 |
| Candriam S.C.A. | 313,765 | 0 |
| Northern Trust Corp | 309,775 | +33,900 |
| Jacobs Levy Equity Management, Inc | 305,434 | +1,677 |
| Vanguard Portfolio Management LLC | 304,432 | +48,501 |
| Birchview Capital, LP | 281,937 | +207 |
| Vanguard Fiduciary Trust Co | 264,422 | +23,836 |
| Qube Research & Technologies Ltd | 203,296 | +122,018 |
Insiders
1 insiders reported holding 270,912 shares in total, about $514.7K at the last price.
| Holder | Shares |
|---|---|
| Gottschalk AdrianChief Executive Officer, Director | 270,912270,912 held indirectly |
Questions about FHTX
What does Foghorn Therapeutics Inc. do?
Foghorn Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as FHTX. Its shares trade on NASDAQ under the ticker FHTX.
What is Foghorn Therapeutics Inc.'s net worth?
Foghorn Therapeutics Inc. has a market value (market cap) of $112.8M at the latest share price, and shareholders' equity of -$14.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Foghorn Therapeutics Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $9.4M on revenue of $112.1M, a net margin of 8.4%.
How much revenue does Foghorn Therapeutics Inc. make?
Over the twelve months to September 30, 2026 Foghorn Therapeutics Inc. reported revenue of $112.1M. That is 357.3% more than a year earlier.
When did Foghorn Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Foghorn Therapeutics Inc.'s next earnings report?
Foghorn Therapeutics Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare FHTX with
Follow FHTX
Get an email when Foghorn Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Foghorn Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.